Search filters

Filters
Clear All

Phase

  • 1
  • 1
  • 1
  • 2
  • 5
  • 5

Found 5 Bladder Carcinoma trials

A listing of Bladder Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Sort by:
18 years or above
All genders
Phase 3
Interventional
This study investigates the effectiveness of an investigational medication compared to observation in treating intermediate risk non-muscle invasive bladder cancer (IR-NMIBC). The purpose of this study is to see if the investigational medication can help prevent the cancer from returning after the initial surgical removal of the tumor.Participants in the …
18 years or above
All genders
Phase 1
Interventional
This study investigates the safety of combining immunotherapy and radiation therapy for treating urothelial bladder cancer. The purpose of this study is to determine if it is safe to use both treatments at the same time, which is not the usual approach. Safety will be assessed based on any acute …
18 years or above
All genders
Interventional
This study investigates the treatment of non-muscle invasive bladder cancer. The purpose of this study is to explore the barriers and facilitators affecting treatment compliance and to test a Bacillus Calmette-Guerin (BCG) at-home program. Participants will be divided into two study arms: one focusing on understanding treatment compliance and the …
18 years or above
All genders
Phase 1/2
Interventional
This study investigates an investigational medication designed to treat patients with advanced or metastatic solid tumors. The purpose of this study is to discover if the investigational medication can slow or stop cancer growth and to learn about its safety. The study will focus on various types of advanced cancers, …
18 years - 130 years
All genders
Observational
The purpose of this study is to investigate the effectiveness of an investigational medication in patients with HER2-positive solid tumors that are locally advanced, unresectable, or metastatic. In this study, HER2-positive is identified as IHC 3+. The study focuses on patients who have previously received systemic treatment for their condition …